BDNF and in situ carcinoma: Further in vivo study revealed that combined therapy with CUR and CIS inhibited the mammary tumor growth accompanied by increased peroxisome proliferator-activated receptor gamma (PPAR-γ) expression and decreased brain-derived neurotrophic factor (BDNF) expression in mammary tumors [136].